Cheesman, R. http://orcid.org/0000-0002-6543-0402
Coleman, J. http://orcid.org/0000-0002-6759-0944
Rayner, C. http://orcid.org/0000-0003-2950-343X
Purves, K. L. http://orcid.org/0000-0002-8110-5554
Morneau-Vaillancourt, G. http://orcid.org/0000-0002-5322-6252
Glanville, K. http://orcid.org/0000-0001-8321-9435
Choi, S. W. http://orcid.org/0000-0003-2215-3238
Breen, G. http://orcid.org/0000-0003-2053-1792
Eley, T. C. http://orcid.org/0000-0001-6458-0700
Funding for this research was provided by:
National Institute for Health Research
Maudsley Charity (980)
Medical Research Council (MR/M021475/1, MR/M021475/1, MR/N015746/1)
GSTT charity (TR130505)
Economic and Social Research Council
Fondation Peters
Alexander von Humboldt-Stiftung
Quebec Network on Suicide, Mood Disorders and Related Disorders
Article History
Received: 21 March 2019
Accepted: 20 November 2019
First Online: 4 December 2019
Compliance with ethical standards
:
: G. Breen is a consultant for Eli Lilly. R. Cheesman, J. Coleman, C. Rayner, K. L. Purves, G. Morneau-Vaillancourt, K. Glanville, S. W. Choi and T. C. Eley declare no conflicts of interest.
: All participants gave full informed written consent for participation in the UK Biobank. This study was performed in accordance with the criteria defined by the rules of the UK Biobank.